MediWound's sales dropped in the first nine months of 2026, and it also reported a loss.

MDWD · MediWound

The AI's read

The lower sales came mainly from less development work for the U.S. government. That and the reported loss are concerns. Procurement has begun through Vericel's BARDA contract, and government funding supports work on a room-temperature version of NexoBrid. The share sale adds cash but gives existing owners smaller stakes. These changes point in different directions.